Program
ABI-6250
A development code.
Its studies are mostly in Hepatitis D, Chronic · Hepatitis D, led by Assembly Biosciences.
Furthest: phase 2, since Aug 5, 20263 company-led studies, 2 open or runningNext primary completion: Apr 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Assembly Biosciences | 32 open or running | phase 2since Aug 5, 2026 | Dec 13, 2024 | Apr 2027phase 1 · NCT07850999 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 13, 2024First study: phase 1 study in Hepatitis DFirst studyNCT06740474 · 40 enrolled · New Zealand
- Aug 5, 2026Phase 2 study in Chronic Hepatitis D InfectionPhase 2 reachedNCT07762027 · 80 planned · France, Georgia, Germany and more
- Sep 14, 2026Phase 1 study in Mild Hepatic ImparementNCT07850999 · 20 planned · New Zealand
Ahead
- Apr 2027Primary completion: phase 1 study in Mild Hepatic ImparementNCT07850999
- Jun 2027Primary completion: phase 2 study in Chronic Hepatitis D InfectionNCT07762027
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07850999Mild Hepatic Imparement · New Zealand | 1 | Not yet recruiting | Apr 2027 | 20 |
| NCT07762027Chronic Hepatitis D Infection · France, Georgia, Germany and more | 2 | Not yet recruiting | Jun 2027 | 80 |
| NCT06740474Hepatitis D · New Zealand | 1 | Completed | Jul 8, 2025 | 40 |
How it is read
Names in the registry
- “ABI-6250”, 4 entries
Codes read as this program: ABI6250.
Conditions, from the studies’ own filings
- Hepatitis D, Chronic, 1 study
- Hepatitis D, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.